Skip to main content
Clinical Trials/NCT07257601
NCT07257601Not yet recruitingNot Applicable

The Effect of Transcranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation on Motor Function Rehabilitation in Patients With Locked-in Syndrome

Zhujiang Hospital0 sites72 target enrollmentStarted: November 30, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
72
Primary Endpoint
the efficiency

Study Overview

Brief Summary

This study was a multicenter randomized double-blind, sham controlled trial initiated by Zhujiang Hospital of Southern Medical University. It is planned to recruit 72 eligible patients with atresia syndrome and randomly divide them into four groups according to the ratio of 1:1:1:1. Group 1 received the sequential stimulation of true tDCS and true rTMS, group 2 received the stimulation of sham tDCS and then true rTMS, group 3 received the stimulation of true tDCS and then sham rTMS, and group 4 received the simulated stimulation of sham tDCS and sham rTMS. The patients were treated for 4 weeks, 5 days a week, once a day in the bilateral M1 area, and in the morning and afternoon on the left and right sides respectively. Each tDCS and rTMS treatment lasted for 20 minutes.Various indicators were evaluated before and after the intervention, and the observation and follow-up were conducted 1, 3, and 6 months after the intervention.

Detailed Description

This study was a multicenter randomized double-blind, sham controlled trial initiated by Zhujiang Hospital of Southern Medical University. It is planned to recruit 72 eligible patients with atresia syndrome and randomly divide them into four groups according to the ratio of 1:1:1:1. Group 1 received the sequential stimulation of true tDCS and true rTMS, group 2 received the stimulation of sham tDCS and then true rTMS, group 3 received the stimulation of true tDCS and then sham rTMS, and group 4 received the simulated stimulation of sham tDCS and sham rTMS. The patients were treated for 4 weeks, 5 days a week, once a day in the bilateral M1 area, and in the morning and afternoon on the left and right sides respectively. Transcranial direct current stimulation (tDCS) was performed using a 2 Ma DC stimulator. The anode was placed in the M1 area of the target side (corresponding to the electrode position c3/c4 of the 10-20 EEG system), and the cathode was placed on the contralateral shoulder. The left side was done in the morning and the right side was done in the afternoon. Each tDCS treatment lasted for 20 minutes. The sham stimulation was given current stimulation for 30 seconds and gradually decreased to 0. Repetitive transcranial magnetic stimulation (rTMS) intervention was performed 20 minutes after the end of TDCS treatment. RTMS uses an 8-shaped coil placed in the M1 area of the target side to stimulate at a frequency of 10Hz. Each treatment contains 1600 pulses of stimulation for 4 seconds, with an interval of 26 seconds. The total number of pulses is 1600, lasting for 20 minutes. Each time is once a day in the M1 area of both sides. The sequence is the same as that of TDCS, 5 days a week, and the same lasts for 4 weeks. The stimulation coil was placed at 90 degrees during sham stimulation. Various indicators were evaluated before and after the intervention, and the observation and follow-up were conducted 1, 3, and 6 months after the intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The patients were 18-70 years old, clinically diagnosed as classic or incomplete atresia syndrome, and the onset time was 6 weeks-1 year.
  • •Clear consciousness, effective communication and command response through eye movement or other established methods.
  • •No drugs (sodium, calcium channel blockers or sedatives) that may affect neuromuscular function or brain stimulation effect were used, or the drugs were stably stopped for more than 1 week before enrollment.
  • •The patient or his legal guardian signed the informed consent form and agreed to cooperate in completing all test procedures and evaluations.

Exclusion Criteria

  • •Metal implants (such as cardiac pacemaker, intracranial metal clip, etc.), electronic equipment or other TMS contraindications.
  • •Complicated with severe cognitive impairment (such as dementia) or unable to cooperate to complete the assessment scale test.
  • •Have a history of severe cardiopulmonary dysfunction, mental illness and seizures.
  • •There are other neurodegenerative diseases that affect the recovery of motor function (such as amyotrophic lateral sclerosis, etc.)
  • •Recently (within 1 month) participated in other clinical trials related to neuromodulation therapy.

Arms & Interventions

Group 1

Experimental

true tDCS and true rTMS

Intervention: Repetitive transcranial magnetic stimulation (Device)

Group 1

Experimental

true tDCS and true rTMS

Intervention: Transcranial direct current stimulation (Device)

Group 2

Placebo Comparator

sham tDCS and true rTMS

Intervention: Repetitive transcranial magnetic stimulation (Device)

Group 2

Placebo Comparator

sham tDCS and true rTMS

Intervention: Transcranial direct current stimulation (Device)

Group 3

Placebo Comparator

true tDCS and sham rTMS

Intervention: Repetitive transcranial magnetic stimulation (Device)

Group 3

Placebo Comparator

true tDCS and sham rTMS

Intervention: Transcranial direct current stimulation (Device)

Group 4

Placebo Comparator

sham tDCS and sham rTMS

Intervention: Repetitive transcranial magnetic stimulation (Device)

Group 4

Placebo Comparator

sham tDCS and sham rTMS

Intervention: Transcranial direct current stimulation (Device)

Outcomes

Primary Outcomes

the efficiency

Time Frame: Before intervention, 1-2 days after intervention, and 1, 3, and 6 months after intervention

An increase of 5 points in the Fugl Meyer Assessment (FMA) score or an increase of one level in the House Brackmann Facial Nerve Grading Scale (HBFNGS) score is considered effective through behavioral assessment.

Secondary Outcomes

  • FMA(Before intervention, 1-2 days after intervention, and 1, 3, and 6 months after intervention)
  • HBFNGS(Before the intervention starts, 1-2 days after the intervention ends, and 1, 3, and 6 months after the intervention ends)
  • Modified Barthel Index(Before intervention, 1-2 days after intervention, and 1, 3, and 6 months after intervention)
  • Motor evoked potential(Mep)(Before intervention, 1-2 days after intervention)
  • Assessment of TMS-EEG(TEPs)(Before intervention and 1-2 days after intervention)
  • Assessment of TMS-EEG(oscillation analysis)(Before intervention and 1-2 days after intervention)

Investigators

Sponsor
Zhujiang Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Qiuyou Xie

principal investigator

Zhujiang Hospital

Similar Trials